About OnCusp
OnCusp is a Healthcare company based in New York (United States) founded in 2021. CRO offering clinical development services for oncology drugs. OnCusp has raised $100 million across 1 funding round from investors including Marshall Wace, Orbimed and Novo Holdings. OnCusp offers products and services including CUSP06 and Pipeline Development. Its focus areas include Biopharma Outsourcing, CRO, Clinical Development and Full Service. Its competitors include Aster Insights, CancerVax and Oncotherapeutics; 3 of its 3 listed competitors have raised funding.
Company details
OnCusp cro offering clinical development services for oncology drugs through providing healthcare solutions, biopharma outsourcing, cro, clinical development, full service, and oncology. Prioritizing client-centric approaches, it ensures high-quality outcomes, innovation, and sustainable practices in its field. It continues to evolve, meeting industry challenges with strategic approaches.
- Headquarters New York, United States
- SectorsHealthcare
- Website oncusptx.com
- Social LinkedIn
- Total Equity Funding$100M (USD)
in 1 rounds
- Latest Funding Round$100M (USD), Series A
Jan 2024
- InvestorsMarshall Wace
& 9 more
Products & Services of OnCusp
OnCusp offers a comprehensive portfolio of products and services, including CUSP06 and Pipeline Development.
Drug targeting Platinum-Resistant Ovarian Cancer in clinical trials
Transforms molecules into innovative cancer therapeutics globally
Funding Insights of OnCusp
OnCusp has successfully raised a total of $100M through 1 strategic funding round. The most recent funding activity was a Series A round of $100 million completed in January 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $100M
- Total Rounds 1
- Last Round Series A — $100M
- First Round $100M
(Jan 2024)
- Investors Count 10
All 1 funding rounds of OnCusp with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan 2024 | $100M | Series A | – | Novo Holdings, Orbimed |
10 investors in total: 10 institutional.
Investors in OnCusp
OnCusp has secured backing from 10 investors, including venture fund and institutional investors. Prominent investors backing the company include Marshall Wace, Orbimed and Novo Holdings.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Private equity and venture capital fund focused on the healthcare sector | novoholdings.dk | Hellerup, Denmark | ||
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields. | 1989 | orbimed.com | New York, United States | |
Investments in life sciences, technology, healthtech, and crypto sectors from global locations. | fprimecapital.com | |||
Biotech funding, drug development support, and investment in life sciences. | sofinnova.com | |||
Venture capital is provided to biomedical technology startups. | cataliocapital.com | New York, United States | ||
Long-short equity strategies are managed through specialized hedge funds. | 1997 | mwam.com | London, United Kingdom | |
Limited information is provided about Forge Life Science Partners. | forgelsp.com | |||
| biotrackcapital.com | ||||
Investor details for OnCusp
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of OnCusp
2 dated milestones of OnCusp across 3 years, from founding to its latest funding, stage changes and deals.
- Founded OnCusp is founded.
- Funding First funding round of $100.0M.
Competitors of OnCusp
OnCusp has 3 listed competitors in our database, 3 of them funded. They include Aster Insights, CancerVax and Oncotherapeutics.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| asterinsights.com | 2006 | Tampa, United States | $75M | 115 | Contract-based oncology clinical trial services are provided by Aster Insights. | |
| cancervax.com | 1998 | Carlsbad, United States | $55M | Cancer vaccine research and development is conducted by CancerVax. | ||
| oncotherapeutics.com | 1988 | West Hollywood, United States | $8.3M | Preclinical and clinical oncology drug development services are provided. |
Detailed competitors of OnCusp
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of OnCusp
The website of OnCusp (oncusptx.com) receives about 1.8K visits a month.
- Monthly visits1.8K
▲ 21.6% vs previous month
Top companies in Biopharma Outsourcing & Drug Delivery
3 companies that operate in the same segment as OnCusp (Biopharma Outsourcing & Drug Delivery) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Suite solutions are provided for payers and healthcare providers. | 1998 | Princeton, New Jersey, United States | USD 220 M | USD 374.1 M | 5,666 | |
Wearable insulin infusion systems are developed for diabetes patients. | 2000 | Boston, Massachusetts, United States | USD 120.4 M | USD 2.71 B | 3,900 | |
Developer of small-molecule drugs | 1991 | Los Angeles, California, United States | USD 50 M | USD 348.97 M | 407 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Oncusp
Complete news archive for OnCusp
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about OnCusp
OnCusp was founded in 2021 and raised its 1st funding round 3 years after it was founded.
OnCusp is headquartered in New York, United States. It is registered at New York, New York, United States.
OnCusp is a funded company, having raised a total of $100M across 1 funding round to date. The company's 1st funding round was a Series A of $100M, raised on Jan 2024.
OnCusp cro offering clinical development services for oncology drugs through providing healthcare solutions, biopharma outsourcing, cro, clinical development, full service, and oncology. Prioritizing client-centric approaches, it ensures high-quality outcomes, innovation, and sustainable practices in its field. It continues to evolve, meeting industry challenges with strategic approaches.
OnCusp's top competitors include CancerVax, Aster Insights and Oncotherapeutics.
OnCusp offers CUSP06 and Pipeline Development.
OnCusp has 10 investors. Key investors include Marshall Wace, Orbimed, Novo Holdings, F-Prime Capital, and Sofinnova.